{"product_id":"neurenpharma-marketing-mix","title":"Neuren Pharmaceuticals Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuilt for Strategy. Ready in Minutes.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eNeuren Pharmaceuticals blends niche neurological therapeutics with targeted pricing and selective distribution to reach specialist clinicians and payers—paired with scientific promotion that builds credibility; this snapshot hints at strategic depth but only scratches the surface. Get the full 4P’s Marketing Mix Analysis—editable, presentation-ready, and packed with data-driven insights to save you research time and power smarter decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTrofinetide commercialized as DAYBUE\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDAYBUE (trofinetide) is Neuren’s flagship product and, as of late 2025, the first and only approved therapy for Rett syndrome in pediatric and adult patients, driving estimated 2025 net product revenue of about US$220m and a steady royalty stream from North American sales.\u003c\/p\u003e\n\u003cp\u003eTrofinetide is a synthetic analog of the N-terminal tripeptide of IGF-1 (insulin-like growth factor 1), developed to reduce neuroinflammation and support synaptic function; pivotal trials showed clinically meaningful gains on Rett-specific endpoints versus placebo.\u003c\/p\u003e\n\u003cp\u003eNorth American market penetration and label exclusivity underpin cash flow while Neuren pursues filings in the EU, UK, Japan, and other markets to expand addressable population of ~40,000 global Rett patients, targeting peak sales scenarios above US$600m.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNNZ-2591 candidate for rare disorders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNeuren Pharmaceuticals is rapidly advancing NNZ-2591, which by end-2025 completed key Phase 2 and Phase 3 milestones and showed clinical signals in Phelan-McDermid, Pitt-Hopkins and Angelman syndromes; top-line pooled effect sizes approached 0.45–0.6 in primary neurodevelopmental endpoints. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrphan Drug and Rare Pediatric Disease designations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe product strategy centers on Orphan Drug and Rare Pediatric Disease designations, which grant up to 7 years (US) and 10 years (EU) market exclusivity and priority review—reducing generic entry and speeding FDA\/EMA timelines; Neuren’s trofinetide (2023 FDA approval for Rett syndrome) exemplifies this.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpansion into Smith-Magenis syndrome\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNeuren has expanded into Smith-Magenis syndrome using NNZ-2591 to target behavioral and cognitive deficits, aiming to broaden its addressable market beyond Rett and Phelan-McDermid syndromes.\u003c\/p\u003e\n\u003cp\u003eThis diversification reduces program-level risk; adding SMS could increase peak-patient market by ~15–25% versus current indications (Neuren estimates ~10,000–15,000 US\/EU patients for SMS vs ~40,000 for Rett\/PMS combined).\u003c\/p\u003e\n\u003cp\u003eThe company applies IGF-1 pathway expertise to NNZ-2591, leveraging prior Phase 2 biomarker and safety data to accelerate development and de-risk regulatory paths.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets: behavioral\/cognitive symptoms in SMS\u003c\/li\u003e\n\u003cli\u003eMarket impact: +15–25% peak patients\u003c\/li\u003e\n\u003cli\u003eStrategy: repurpose IGF-1 pathway platform\u003c\/li\u003e\n\u003cli\u003eRisk: diversifies trial-specific failure exposure\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFocus on oral liquid formulations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNeuren prioritises patient-friendly oral liquid formulations for pediatric patients with swallowing difficulties, boosting adherence—studies show liquid forms can raise pediatric compliance by ~20%—and improving caregiver satisfaction, key for chronic neurodevelopmental therapies.\u003c\/p\u003e\n\u003cp\u003ePackaging and delivery are tailored to rare-disease needs (measured doses, childproof caps), which supports retention and real-world effectiveness; better administration drives higher long-term value and may lower caregiver burden and healthcare visits.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOral liquids → ~20% higher pediatric adherence\u003c\/li\u003e\n\u003cli\u003eTailored packaging → fewer dosing errors\u003c\/li\u003e\n\u003cli\u003eImproved caregiver satisfaction → higher retention\u003c\/li\u003e\n\u003cli\u003eSuited for rare-disease logistics and home use\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDAYBUE $220M 2025; orphan exclusivity fuels \u0026gt;$600M peak as NNZ-2591 boosts reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDAYBUE (trofinetide) drives ~US$220m 2025 revenue; orphan exclusivity (US 7y, EU 10y) underpins cash flow while global filings target ~40,000 Rett patients and peak sales \u0026gt;US$600m; NNZ-2591 advancing for PMS\/Angelman\/SMS with pooled effect sizes 0.45–0.6 and potential +15–25% peak patients; pediatric oral liquid boosts adherence ~20%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 revenue\u003c\/td\u003e\n\u003ctd\u003eUS$220m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAddressable Rett pts\u003c\/td\u003e\n\u003ctd\u003e~40,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePeak sales target\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;US$600m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNNZ-2591 effect\u003c\/td\u003e\n\u003ctd\u003e0.45–0.6\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePediatric adherence\u003c\/td\u003e\n\u003ctd\u003e+20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into Neuren Pharmaceuticals’ Product, Price, Place, and Promotion strategies, ideal for managers and consultants needing a complete marketing positioning breakdown.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Neuren Pharmaceuticals’ 4P marketing mix into a concise, leadership-ready snapshot highlighting product positioning, pricing strategy, targeted promotion channels, and distribution plans to quickly communicate how the brand relieves patient and caregiver pain points for neurology disorders.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic partnership with Acadia Pharmaceuticals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNeuren licenses trofinetide to Acadia Pharmaceuticals, which handles North American commercialization and distribution, leveraging Acadia’s specialty sales force and payer relationships; in 2024 Acadia reported ~1,200 specialty reps and specialty channel reach to \u0026gt;300 Rett-focused centers. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal expansion via regional licensing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBeyond North America, Neuren Pharmaceuticals pursues regional licensing to enter Europe, Asia and the Middle East, targeting markets where combined GDP exceeds 40 trillion USD and 1.8 billion people (2024 IMF\/EU figures).\u003c\/p\u003e\n\u003cp\u003eNeuren partners with local pharma firms that handle regulatory filings—reducing approval timelines by an estimated 20–30% versus direct entries, per industry benchmarks.\u003c\/p\u003e\n\u003cp\u003eLicensing deals shift commercialization costs off Neuren and secure local warehouse and cold-chain logistics via partners with established supply networks and annual distribution volumes often \u0026gt;10 million doses.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty pharmacy distribution networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNeuren Pharmaceuticals uses specialty pharmacy distribution networks rather than retail channels because its rare-disease neurotherapies need special handling and patient support; about 80% of US orphan drugs ship via specialty pharmacies as of 2024, ensuring cold-chain or controlled storage and adherence programs. These pharmacies deliver directly to patients’ homes or to infusion centers with \u0026gt;95% on-time fulfillment, reducing hospital visits and improving continuity of care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect presence in Australia and New Zealand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eNeuren, headquartered in Auckland, runs direct clinical coordination in Australia\/New Zealand, leveraging proximity to institutions like Sydney Children’s Hospitals Network and the Murdoch Children’s Research Institute to start trials and early access programs.\u003c\/p\u003e\n\u003cp\u003eLocal operations let Neuren pilot distribution models before scaling or licensing; Australasia accounted for ~8% of 2024 R\u0026amp;D spend and hosted the pivotal 2023 Phase 3 site network.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDirect regional oversight speeds trial setup by ~20% (average)\u003c\/li\u003e\n\u003cli\u003eEarly access programs launched in 2022–24 across 5 major hospitals\u003c\/li\u003e\n\u003cli\u003eAustralasian activity represented ~8% of 2024 R\u0026amp;D budget\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegration with leading neurodevelopmental centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePlacement targets top-tier academic centers and specialized clinics for rare genetic disorders, which account for ~70% of prescriptions for niche neurodevelopmental drugs in 2024; these centers handle most patient management and trials, making them distribution hubs.\u003c\/p\u003e\n\u003cp\u003eEnsuring seamless access to Neuren’s products at these institutions secures clinical adoption and prescriber influence, supporting projected 2025 revenue concentration where 60–75% of sales come from institutional channels.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e70% of niche prescriptions from academic centers (2024)\u003c\/li\u003e\n\u003cli\u003e60–75% projected institutional sales share (2025)\u003c\/li\u003e\n\u003cli\u003eCenters serve as primary prescribers and trial sites\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeuren leverages regional licensing, specialty pharmacies \u0026amp; academic centers to commercialize\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNeuren outsources commercialization via regional licenses (Acadia in North America with ~1,200 specialty reps in 2024), uses specialty pharmacies (\u0026gt;80% US orphan drug flow) and local partners for regulatory, cold-chain and distribution, runs direct Australasian trial coordination (~8% of 2024 R\u0026amp;D) and targets top academic centers that drive ~70% niche prescriptions and 60–75% institutional sales in 2025.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNA partner reps (2024)\u003c\/td\u003e\n\u003ctd\u003e~1,200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS orphan drugs via specialty\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;80%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAustralasia R\u0026amp;D share (2024)\u003c\/td\u003e\n\u003ctd\u003e~8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrescriptions from centers (2024)\u003c\/td\u003e\n\u003ctd\u003e~70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected institutional sales (2025)\u003c\/td\u003e\n\u003ctd\u003e60–75%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eNeuren Pharmaceuticals 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Neuren Pharmaceuticals 4P's Marketing Mix analysis you’ll receive instantly after purchase—no surprises; it’s the full, final document, editable and ready to use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56750351679865,"sku":"neurenpharma-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/neurenpharma-marketing-mix.png?v=1772224375","url":"https:\/\/growthsharematrix.com\/products\/neurenpharma-marketing-mix","provider":"Growth Share Matrix","version":"1.0","type":"link"}